Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.
about
Short chain fatty acids (butyrate) for induction of remission in ulcerative colitisProbiotics and irritable bowel syndromeSynbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trialMicrobiota-based treatments in alcoholic liver diseaseGenetic update on inflammatory factors in ulcerative colitis: Review of the current literatureStructural and immunomodulatory differences among lactobacilli exopolysaccharides isolated from intestines of mice with experimentally induced inflammatory bowel diseaseDistinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States.Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats.Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors.A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis.Association of levels of antibodies from patients with inflammatory bowel disease with extracellular proteins of food and probiotic bacteria.Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice.TLR2 and interleukin-10 are involved in Bacteroides fragilis-mediated prevention of DSS-induced colitis in gnotobiotic mice.Probiotics and prebiotics in chronic inflammatory bowel diseases.Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets.Anisotropic nutrient transport in three-dimensional single species bacterial biofilms.Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients.Inulin and oligofructose: impact on intestinal diseases and disorders.Mechanisms of disease: the hygiene hypothesis revisited.Mechanisms of action of probiotics: recent advances.Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk.Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expressionStimulation of duodenal biopsies and whole blood from dogs with food-responsive chronic enteropathy and healthy dogs with Toll-like receptor ligands and probiotic Enterococcus faecium.Probiotics and human health: a clinical perspective.Growth promotion and gut microbiota: insights from antibiotic use.Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritisMucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acidProbiotics in inflammatory bowel disease: is it all gut flora modulation?Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.Goat Milk Yoghurt by Using Lacto-B Culture Modulates the Production of Tumor Necrosis Factor-Alpha and Interleukin-10 in Malnourished Rats.Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.The role of gut-associated lymphoid tissues and mucosal defence.Preclinical Immunomodulation by the Probiotic Bifidobacterium breve M-16V in Early LifeQuorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model.Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaLactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa
P2860
Q24234780-463DCFF2-57C5-45E2-A9C6-08C7F66D7C37Q24616349-F3DD5E99-6B32-4023-A75B-AAB277856891Q24685494-AC1B09CA-CE89-4D7B-BD5E-D80BFB25F471Q26740192-A5E75C0E-0CCC-447B-9EAA-C57BFB45C4CFQ26852514-E7C98BE5-F001-44C4-8F08-C0F8771D3B85Q28821002-3C466621-C7EE-4766-9E70-11E12AE2A47BQ30422767-F75E8AE3-3005-422F-8844-C7396CA3A3E5Q31142368-ABF45061-2DA0-4B8B-A8EF-FCDB5D066C37Q33231186-358F6B31-FB5C-4F5E-ABDE-F5C60C416334Q33261861-EA3A3B9A-CD8C-47A9-A0C8-45F1648B84FDQ33432739-CA3C26F4-3006-4346-B230-1D7359FB9475Q33434046-1CA8126A-1BF2-4C0E-B6C5-93E8755CE769Q33468052-FFDDE19F-3738-458C-81AD-AF441794AD46Q33787065-1E5A593E-B711-4B3D-9A76-422D64137EC7Q33795727-67B22832-06AD-4296-8665-F8BC77A2CE62Q33880555-7C2D032B-D788-455C-AE16-DE58DF0E3013Q34013030-3EF99C54-C618-4961-966E-43F766A393BCQ34020518-2119993F-5747-4A3F-820C-60864ACDF331Q34085452-4C0FECB5-23B9-4862-BDFB-0A3E689878D0Q34104678-5442B3FB-FEDA-48CA-BA9C-E3C5264246CFQ34416504-01270E21-A80E-49F4-96F3-78775DA0F617Q34652218-5D8EDE75-B47A-4D6C-90B3-422F7A84351DQ34796044-50297757-9153-4701-8D2A-08B034E6AAE3Q34973957-437E44CA-1321-4CD5-8F42-EBAA221941E3Q35059717-AB60AA2D-1C88-4EC8-BEDE-A4E46EEDDA25Q35067850-132CB9A4-49BB-4D60-98C4-7159C95CA679Q35165968-9C70AB5B-38AC-41AF-BF69-9A8AD9CC764DQ35520339-5B24CD30-F044-4C1C-8762-C5BAA1ED6740Q35550444-EB9B492E-2FE6-4F57-8817-06E7110C6280Q35596470-F91C511E-CE4B-4C74-BE2B-5A821E2E6FEFQ35597617-8DDC9237-03BD-494D-95B2-19092226EEE2Q35745012-78C84788-4969-4641-A237-8AEF8BB3E98CQ35760524-5235F3EF-CADD-4084-9A47-A4C1C612F547Q35892618-9437F26C-B857-4536-8A2B-334772ACCA1FQ36009729-F31FFE95-1D71-43DD-AF90-2B110BCFEEE4Q36118690-C541B632-7037-49A9-BF2D-AC6A86459EADQ36184388-2DDFC479-F27F-4811-BC57-6F3D939020DBQ36346261-02BEABA7-7DBC-4CC6-8913-2EE8CBF6A1CAQ36403491-D7E81F2D-7B24-4441-8157-C744549A9513Q36620029-F30B0789-8875-4FC7-BB8E-0BC5C998E92F
P2860
Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@ast
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@en
type
label
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@ast
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@en
prefLabel
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@ast
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@en
P2093
P2860
P921
P356
P1433
P1476
Increased mucosal tumour necro ...... ex vivo by probiotic bacteria.
@en
P2093
F Casellas
J R Malagelada
P2860
P304
P356
10.1136/GUT.51.5.659
P407
P577
2002-11-01T00:00:00Z